To validate if oncogenic NF-κB signaling is indeed downregulated following AZD8186 treatment, we analyzed nuclear RelA and p50 levels in two sensitive (OCI-Ly10 and TMD8) and one resistant (OCI-Ly3) ABC DLBCL cell line. This evidence concerns the gene RELA and diffuse large B-cell lymphoma.